CXCR1

C-X-C chemokine receptor type 1 · P25024 · CXCR1 on Sugi Atlas →

36,988 patent compounds predicted against CXCR1, 22,014 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL248828 SCHEMBL248828 1.00 19/20
SCHEMBL247339 SCHEMBL247339 1.00 18/20
SCHEMBL248562 SCHEMBL248562 1.00 18/20
SCHEMBL248693 SCHEMBL248693 0.81 18/20
Navarixin Anhydrous Navarixin Anhydrous (SCHEMBL184744) 1.00 17/20
SCHEMBL248387 SCHEMBL248387 1.00 17/20
SCHEMBL246919 SCHEMBL246919 0.81 15/20
SCHEMBL248850 SCHEMBL248850 0.72 15/20
SCHEMBL246917 SCHEMBL246917 0.81 14/20
SCHEMBL677562 SCHEMBL677562 0.56 13/20
SCHEMBL247336 SCHEMBL247336 0.67 12/20
SCHEMBL247103 SCHEMBL247103 1.00 11/20
SCHEMBL248295 SCHEMBL248295 1.00 11/20
SCHEMBL248399 SCHEMBL248399 0.69 11/20
SCHEMBL248274 SCHEMBL248274 0.66 11/20
SCHEMBL247335 SCHEMBL247335 0.64 9/20
SCHEMBL248807 SCHEMBL248807 0.83 8/20
SCHEMBL175199 SCHEMBL175199 0.46 8/20
SCHEMBL677623 SCHEMBL677623 0.51 7/20
SCHEMBL247709 SCHEMBL247709 0.63 6/20

Clinical trials — most relevant to CXCR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar PHASE2/PHASE3UNKNOWN
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) PHASE1/PHASE2RECRUITING
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC PHASE2ACTIVE_NOT_RECRUITING
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma PHASE1/PHASE2COMPLETED
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer PHASE1UNKNOWN
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma PHASE1COMPLETED
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) PHASE1COMPLETED
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study EARLY_PHASE1RECRUITING
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma EARLY_PHASE1UNKNOWN
Application of 68Ga-Pentixafor PET/CT for Thymoma EARLY_PHASE1UNKNOWN
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases EARLY_PHASE1UNKNOWN
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib nanCOMPLETED
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE nanUNKNOWN
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA nanRECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination. nanENROLLING_BY_INVITATION
Comparative Study Between Alzheimer's and Multi-infarct Dementia nanUNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases nanRECRUITING
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease nanCOMPLETED
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
Preliminary Study of CXCL3 As a Biomarker of Diabetic Kidney Disease nanCOMPLETED
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis nanNOT_YET_RECRUITING
Activation and Recruitment of GIL During Hp Infection nanUNKNOWN
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CXCR1 binder may also engage these)

ProteinNameSimilarity
P55920 1.000 P55920 →
Q2YEF9 1.000 Q2YEF9 →
Q2YEG2 1.000 Q2YEG2 →
P55919 1.000 P55919 →
Q2YEG0 1.000 Q2YEG0 →
CXCR2 C-X-C chemokine receptor type 2 1.000 landscape →
Q28003 1.000 Q28003 →
P21109 1.000 P21109 →
O97571 0.998 O97571 →
P70612 0.998 P70612 →
Q28807 0.997 Q28807 →
Q28519 0.997 Q28519 →
P35344 0.996 P35344 →
Q28422 0.995 Q28422 →
Q1ZY22 0.995 Q1ZY22 →
Q810W6 0.994 Q810W6 →
P56493 0.993 P56493 →
P35407 0.993 P35407 →
P35343 0.993 P35343 →
Q95ND1 0.993 Q95ND1 →
P61815 0.993 P61815 →
Q95NC6 0.993 Q95NC6 →
P61813 0.993 P61813 →
P61814 0.993 P61814 →
Q3LSL6 0.992 Q3LSL6 →
P56498 0.992 P56498 →
O97878 0.992 O97878 →
O54814 0.992 O54814 →
Q764M9 0.992 Q764M9 →
P35411 0.992 P35411 →